Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Beigene Ltd ADR
(NQ:
BGNE
)
160.93
+6.19 (+4.00%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Beigene Ltd ADR
< Previous
1
2
3
4
5
6
7
Next >
BRUKINSA® Approved in Canada for the Treatment of Chronic Lymphocytic Leukemia
May 30, 2023
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Presentations at the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio
May 25, 2023
From
BeiGene
Via
Business Wire
BeiGene to Present at Upcoming Investor Conferences
May 24, 2023
From
BeiGene
Via
Business Wire
Beigene Ltd. (NASDAQ: BGNE) Highlighted for Surprising Price Action
April 06, 2023
Via
Investor Brand Network
The Max Foundation, BeiGene, and the BeiGene Foundation Announce Collaboration to Advance Health Equity by Providing Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries
May 17, 2023
From
BeiGene
Via
Business Wire
BeiGene Receives New Approvals for BRUKINSA® (zanubrutinib) in China
May 06, 2023
From
BeiGene
Via
Business Wire
BeiGene Reports First Quarter 2023 Financial Results and Corporate Developments
May 04, 2023
From
BeiGene, Ltd.
Via
Business Wire
BeiGene to Highlight Broad Oncology Portfolio at the 2023 ASCO Annual Meeting
April 26, 2023
From
BeiGene
Via
Business Wire
BeiGene Announces Goals Focused on Sustainable Growth and Workforce Diversity in New ESG Report
April 25, 2023
From
BeiGene
Via
Business Wire
BeiGene Announces Positive Phase 3 Tislelizumab Trial in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
April 20, 2023
From
BeiGene
Via
Business Wire
BeiGene and SpringWorks Present Clinical Data on Lifirafenib, in Combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023
April 17, 2023
From
BeiGene, Ltd.
Via
Business Wire
SpringWorks and BeiGene Present Clinical Data on Lifirafenib, in combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023
April 17, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
MapKure, BeiGene and SpringWorks Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023
April 17, 2023
From
BeiGene
Via
Business Wire
MapKure, SpringWorks and BeiGene Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023
April 17, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
BeiGene Expands Presence in Latin America With Opening of Brazil Office
April 13, 2023
From
BeiGene
Via
Business Wire
BeiGene Appoints Julius Pryor III as First Global Head of Diversity and Health Equity
March 30, 2023
From
BeiGene
Via
Business Wire
BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey
March 21, 2023
From
BeiGene
Via
Business Wire
BeiGene Reports Fourth Quarter and Full Year 2022 Financial Results
February 27, 2023
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Receives 10th Approval for PD-1 Inhibitor Tislelizumab in China
February 24, 2023
From
BeiGene
Via
Business Wire
BeiGene to Present at Cowen’s 43rd Annual Healthcare Conference
February 24, 2023
From
BeiGene
Via
Business Wire
New Talk About It Resources Aim to Accelerate Integration of Mental Health into Quality Cancer Care
February 03, 2023
From
BeiGene
Via
Business Wire
BeiGene to Present at Upcoming Investor Conferences
February 01, 2023
From
BeiGene
Via
Business Wire
BRUKINSA® Approved in the U.S. for Chronic Lymphocytic Leukemia
January 19, 2023
From
BeiGene
Via
Business Wire
BRUKINSA® (zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leukemia (CLL) and Marginal Zone Lymphoma (MZL) in Great Britain by MHRA
January 19, 2023
From
BeiGene
Via
Business Wire
BeiGene Announces Expansion of Coverage on China’s National Reimbursement Drug List
January 18, 2023
From
BeiGene
Via
Business Wire
BeiGene Presents New Research from Tislelizumab Global Development Program at 2023 ASCO Gastrointestinal Cancers Symposium
January 17, 2023
From
BeiGene
Via
Business Wire
BeiGene to Present at the J.P. Morgan 41st Annual Healthcare Conference
January 04, 2023
From
BeiGene
Via
Business Wire
BeiGene Announces Acceptance of 12th Regulatory Submission in China for PD-1 Inhibitor Tislelizumab
December 30, 2022
From
BeiGene
Via
Business Wire
BeiGene’s BRUKINSA® (zanubrutinib) Demonstrated Superior Progression-Free Survival Over IMBRUVICA® (ibrutinib) in Chronic Lymphocytic Leukemia in Late-Breaker at ASH
December 13, 2022
From
BeiGene
Via
Business Wire
BeiGene Calls for Greater Integration of Mental Health in Cancer Care After New Survey Reveals Gaps/Barriers for Patients and Survivors
December 09, 2022
From
BeiGene
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.